Boyer and Gotoff as well as that of Strickland et al. and Yancey and Duff similarly support this contention. Based on the high cost of caring for neonates with early-onset disease ($22,000-33,800), the policy of screening and treatment has been projected to be economically justified. 1'6 Gibbs et al. reviewed the 2-year experience of a universal screening program with strict application of criteria and found the compliance rate in administering indicated prophylaxis with a complex algorithm to be only 80.3%. The 
